PLURHealthcare · Biotechnology

PLUR Stock Forecast: Pluri, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026

$1.08

0.00% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 19 Sept 2026 — in the weakest quartile.

Market cap

$13.3M

Ticker Nerd rank

15 / 100

Median analyst target

—

Analysts covering

Revenue$335K−15.8% y/y

Operating income−$5.5M

Net income−$6.2M

Free cash flow−$4.5M

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−8.5%

−33.7%

YTD

−63.9%

−76.0%

From 52W high

−77.1%

From 52W low

0.0%

$1.08

$4.71

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

PLUR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pluri, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026

15 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Volatility

Revisions

Issuance

Value

Quality

Momentum

Size (91): Smaller than most of the companies we track.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PLUR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PLUR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
2 June 2025	Alliance Global Partners	Initiates	Buy	$12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PLUR appears on the weeks it earns a place.

Performance

PLUR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Pluri, Inc. returned −76.0% against +16.3% for the S&P 500, dividends included.

PLUR vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PLUR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Pluri, Inc. (PLUR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.3×
Price / sales: 13.1×
Price / book: −1.0×
EV / EBITDA: −1.9×

Growth & margins

Revenue growth (YoY): −15.8%
Earnings growth (YoY): —
Gross margin: 58.5%
Operating margin: −1655.5%
Net margin: 44.6%

Returns & dividend

Return on equity: 136.6%
Return on assets: −49.0%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pluri, Inc. (PLUR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Pluri, Inc. has a market value of $13.3M and an enterprise value of $46.0M.
Revenue in the twelve months to 30 June 2026: $1.0M. The latest quarter shrank 15.8% year on year.
Net income over the same four quarters: −$25.4M, a −2496.9% net margin.
Free cash flow in the twelve months to 30 June 2026: −$20.2M.
Shares outstanding: 10.8M.
Trailing P/E: −0.3×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Pluri, Inc. employs 92 people — $11K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

PLUR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
PLURPluri, Inc.	$13.3M	15
INTSIntensity Therapeutics, Inc.	$13.4M	23
CALCCalciMedica, Inc.	$13.1M	27
ENLVEnlivex Ltd.	$13.6M	41
BIVIBioVie, Inc.	$13.6M	25
GTBPGT Biopharma, Inc.	$12.9M	16
ADILAdial Pharmaceuticals, Inc.	$12.8M	21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pluri, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PLUR news & analysis

Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor

GlobeNewsWire · 27 Aug 2026neutral

Pluri announced a securities purchase agreement with a single healthcare-focused institutional investor for a registered direct offering of 2,228,940 common shares at $1.50 per share, expected to generate approximately $3.3 million in gross proceeds before fees and expenses.

Why it matters — This offering provides Pluri with fresh capital via a healthcare-focused institutional investor, which PLUR watchers would track for the company's funding and dilution impact.

Plurilock Security Inc. (PLUR:CA) Discusses Corporate Update and Growth Strategy in Defense Contracting Portfolio Transcript

Seeking Alpha · 20 Aug 2026neutral

Plurilock Security Inc. presented a corporate update and discussed its growth strategy within its defense contracting portfolio, as covered in a Seeking Alpha transcript of the discussion.

Why it matters — PLUR watchers would be interested because the company outlined its approach and direction for its defense contracting business, which is a key part of its portfolio.

Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment

GlobeNewsWire · 17 Aug 2026positive

Pluri's majority-owned food-tech company, Ever After Foods, has expanded its cultivated-protein platform through the acquisition of Fishway and a strategic investment. This adds aquatic cell biology, animal-component-free media capabilities, and a European scientific presence to the company.

Why it matters — For Pluri watchers, this expansion broadens Ever After Foods' cultivated-protein capabilities and geographic scientific reach under the company's majority ownership.

Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK

GlobeNewsWire · 28 July 2026positive

Pluri's consumer-health subsidiary, Cellav, completed regulatory registration in the UK for its regenerative aesthetics product Regenativo+, paving the way for a commercial launch in a market estimated at roughly $900 million annually.

Why it matters — This milestone advances Pluri's commercialization strategy by opening a significant new market and laying the groundwork for broader international expansion of its regenerative aesthetics portfolio.

FAQ

Frequently asked questions about PLUR stock

Is PLUR stock a buy right now?

Of the 1 analysts covering Pluri, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pluri, Inc. 15 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PLUR?

As at 19 Sept 2026, Pluri, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

What is the PLUR stock forecast for 2030?

No analyst covering Pluri, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PLUR are extrapolating price history, which says nothing about the business.

How has PLUR stock performed over the past year?

Pluri, Inc. returned -76.0% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pluri, Inc. do?

Pluri Inc. is a biotechnology company focused on the research, development, manufacturing, and commercialization of cell-based products and related technologies.

What is the latest news on PLUR?

The most recent item we track (GlobeNewsWire, 27 Aug 2026): "Pluri Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement with a Single Healthcare Focused Institutional Investor". Pluri announced a securities purchase agreement with a single healthcare-focused institutional investor for a registered direct offering of 2,228,940 common shares at $1.50 per share, expected to generate approximately $3.3 million in gross proceeds before fees and expenses.

Company

About Pluri, Inc.

Pluri Inc. is a biotechnology company focused on the research, development, manufacturing, and commercialization of cell-based products and related technologies. The company uses its proprietary three-dimensional cell expansion platform to support scalable cell production for applications across regenerative medicine, immunotherapy, food technology, and agricultural technology. Its current business areas include cell therapeutics, cultivated food solutions, and contract development and manufacturing services, reflecting a diversified platform built around advanced cell engineering. Pluri Inc. serves markets that rely on biological innovation to address medical, industrial, and sustainability challenges, positioning itself as a provider of cell-based solutions for both therapeutic and non-therapeutic uses. Headquartered in Haifa, Israel, Pluri Inc. operates as a clinical-stage biotechnology company with a focus on translating cell technology into practical commercial products and services.

CEO Mr. Yaacov Yanay · 92 employees · Israel · https://www.pluri-biotech.com